Home » Stocks » GRTS

Gritstone Oncology, Inc. (GRTS)

Stock Price: $9.25 USD -0.06 (-0.64%)
Updated Apr 23, 2021 9:36 AM EDT - Market open
Market Cap 457.21M
Revenue (ttm) 4.04M
Net Income (ttm) -105.31M
Shares Out 37.79M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 23
Last Price $9.25
Previous Close $9.31
Change ($) -0.06
Change (%) -0.64%
Day's Open -
Day's Range 9.15 - 9.25
Day's Volume 10,526
52-Week Range 2.54 - 35.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Preliminary Data from Phase 1 Study of CORAL Expected Mid-year –

3 weeks ago - GlobeNewsWire

Why? They're focusing on one of the biggest coronavirus problems.

Other stocks mentioned: INO, NVAX
1 month ago - The Motley Fool

They're off to a good start.

Other stocks mentioned: OCGN, ZOM
1 month ago - The Motley Fool

Here's why these highfliers could have more fuel in the tank.

Other stocks mentioned: AMTI, MRNA
1 month ago - The Motley Fool

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 0.00% and 12.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

EMERYVILLE, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunother...

1 month ago - GlobeNewsWire

EMERYVILLE, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease imm...

1 month ago - GlobeNewsWire

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.

Other stocks mentioned: ABT, MRNA, RDHL
2 months ago - The Motley Fool

Gilead Sciences announced a partnership in HIV with Gritstone Oncology, and upped its stake in Arcus Biosciences. Biotech stock Arcus jumped, but Gritstone fell at the stock market's close.

2 months ago - Investors Business Daily

FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next genera...

Other stocks mentioned: GILD
2 months ago - Business Wire

Gritstone Oncology (GRTS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

2 months ago - Zacks Investment Research

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Bank of America and Netflix

Other stocks mentioned: NFLX, BAC, LITE, PRGS
2 months ago - CNBC

The coronavirus presents one big risk in the future. This vaccine maker is tackling it.

3 months ago - The Motley Fool

Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.

3 months ago - Zacks Investment Research

— Deal provides nonexclusive access to Genevant's leading LNP technology for use in Gritstone's self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in...

3 months ago - GlobeNewsWire

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other stocks mentioned: ACRS, CYAD, MRUS, NERV, TENX
3 months ago - Benzinga

Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.

3 months ago - The Motley Fool

--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developi...

3 months ago - GlobeNewsWire

--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Gritstone...

3 months ago - GlobeNewsWire

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mu...

4 months ago - GlobeNewsWire

Shareholders of 36KR Holdings Inc (NASDAQ:KRKR) and Gritstone Oncology Inc (NASDAQ:GRTS) have seen their holdings tumble more than 59% over the past 12 months, but analysts still recommend to buy these ...

Other stocks mentioned: KRKR
4 months ago - GuruFocus

EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mu...

5 months ago - GlobeNewsWire

-- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritston...

5 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology , Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fi...

7 months ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight...

7 months ago - GlobeNewsWire

It's Time To Buy Gritstone Oncology As First Vaccine Treated Colorectal Cancer Patient Nears RECIST Confirmed Response

7 months ago - Seeking Alpha

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 10.39% and -59.33%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...

8 months ago - GlobeNewsWire

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mult...

8 months ago - GlobeNewsWire

Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For

9 months ago - Seeking Alpha

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

Other stocks mentioned: AZN, IBB, NVAX, REGN, SNY
9 months ago - 24/7 Wall Street

If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and our deep ...

Other stocks mentioned: AGEN, BLNK, MNKD, OCGN
10 months ago - Forbes

EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...

10 months ago - GlobeNewsWire

Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

EMERYVILLE, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight m...

11 months ago - GlobeNewsWire

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019.

1 year ago - Zacks Investment Research

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...

1 year ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight mul...

1 year ago - GlobeNewsWire

EMERYVILLE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight...

1 year ago - GlobeNewsWire

The pricing of a secondary stock offering is taking a toll on the biotech stock.

1 year ago - The Motley Fool

About GRTS

Gritstone Oncology, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors,... [Read more...]

Industry
Biotechnology
IPO Date
Sep 28, 2018
CEO
Andrew Allen
Employees
169
Stock Exchange
NASDAQ
Ticker Symbol
GRTS
Full Company Profile

Financial Performance

In 2020, GRTS's revenue was $4.04 million, a decrease of -7.51% compared to the previous year's $4.37 million. Losses were -$105.31 million, 11.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 25.33, which is an increase of 173.84% from the latest price.

Price Target
$25.33
(173.84% upside)
Analyst Consensus: Buy